Management of Antiretroviral
Download
1 / 49

Management of Antiretroviral Therapy – Case Presentations - PowerPoint PPT Presentation


  • 109 Views
  • Uploaded on

Management of Antiretroviral Therapy – Case Presentations. Roy M. Gulick, MD, MPH Weill Medical College of Cornell University. Antiretroviral Therapy: Continuing Questions. When to start? What to start? When to switch? What to switch to? Can you stop therapy?. When to Start? Case 1.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Management of Antiretroviral Therapy – Case Presentations' - uriel-strong


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Management of Antiretroviral Therapy – Case Presentations

Roy M. Gulick, MD, MPH

Weill Medical College of Cornell University


Antiretroviral therapy continuing questions
Antiretroviral Therapy: Continuing Questions

  • When to start?

  • What to start?

  • When to switch?

  • What to switch to?

  • Can you stop therapy?


When to start case 1
When to Start? Case 1

  • 35 year old woman

    • Recently diagnosed

    • History of oral thrush and zoster

    • Never on treatment

    • HIV RNA 20,000

    • CD4 120

  • Do you recommend treatment?


When to start case 2
When to Start? Case 2

  • 35 year old woman

    • Recently diagnosed

    • Asymptomatic

    • Never on treatment

    • HIV RNA 20,000

    • CD4 120

  • Do you recommend treatment?


When to start case 3
When to Start? Case 3

  • 35 year old woman

    • Recently diagnosed

    • Asymptomatic

    • Never on treatment

    • HIV RNA 20,000

    • CD4 420

  • Do you recommend treatment?


Goal of antiretroviral therapy
Goal of Antiretroviral Therapy

  • to suppress HIV RNA (viral load level) as low as possible, for as long as possible

  • to preserve or enhance immune function

  • to delay clinical progression of HIV disease


When to start treatment dhhs

symptomatic

asymptomatic,

HIV RNA >10-20K

or CD4 <500

asymptomatic,

HIV RNA <10-20K

and CD4 >500

treat

offer treatment

delay or treat

When To Start Treatment? -- DHHS

DHHS Guidelines, 1/28/00


Early vs late treatment

EARLY RX:

HIV disease is progressive.

Rx decreases VL (and resistance) and increases CD4 (and immune function).

3+ years of virologic suppression demonstrated.

DELAYED RX:

Risk of clinical progression low in early disease.

Practical factors (adherence, toxicity outweigh benefits in early disease).

Long term effects unknown.

Early vs. Late Treatment

DHHS Guidelines, 1/28/00


What to start case 1
What to Start? Case 1

  • 35 year old woman

    • Recently diagnosed

    • History of oral thrush and zoster

    • Never on treatment

    • HIV RNA 20,000

    • CD4 120


What to start case 1 cont
What to start?Case 1 (cont.)

  • What would you recommend?

    • Indinavir + 2 nucs

    • Nelfinavir + 2 nucs

    • Efavirenz + 2 nucs

    • Nevirapine + 2 nucs

    • Something else


What to start case 2
What to Start? Case 2

  • 35 year old woman

    • Recently diagnosed

    • History of oral thrush and zoster

    • Never on treatment

    • HIV RNA 20,000

    • CD4 120

    • Concerned about her ability to adhere to therapy


What to start case 2 continued
What to start?Case 2 (continued)

  • What would you recommend?

    • Indinavir + 2 nucs

    • Nelfinavir + 2 nucs

    • Efavirenz + 2 nucs

    • Nevirapine + 2 nucs

    • Something else


What to start case 3
What to Start? Case 3

  • 35 year old woman

    • Recently diagnosed

    • History of oral thrush and zoster

    • Never on treatment

    • HIV RNA 20,000

    • CD4 120

    • Recently diagnosed with pulmonary TB, taking INH, RIF, PZA, ETH


What to start case 3 cont
What to start?Case 3 (cont.)

  • What would you recommend?

    • Indinavir + 2 nucs

    • Nelfinavir + 2 nucs

    • Efavirenz + 2 nucs

    • Nevirapine + 2 nucs

    • Something else


Antiretroviral drugs 2000

nucleoside RTIs

zidovudine (AZT, ZDV)

didanosine (ddI)

zalcitabine (ddC)

stavudine (d4T)

lamivudine (3TC)

abacavir (ABC)

NNRTIs

nevirapine

delavirdine

efavirenz

nucleotide RTIs

*tenofovir (PMPA)

protease inhibitors

saquinavir

ritonavir

indinavir

nelfinavir

amprenavir

lopinavir

(ABT-378/r)

ANTIRETROVIRAL DRUGS -- 2000


Dhhs treatment guidelines strongly recommended

Column A

efavirenz

indinavir

nelfinavir

ritonavir + saquinavir

Column B

d4T + 3TC

d4T + ddI

ZDV + 3TC

ZDV + ddI

DHHS Treatment Guidelines:Strongly Recommended

DHHS Guidelines, 1/28/00


Combination rx 3 drug regimens

Study

Regimen

Results (48 wk f/u)

Dupont 006

(N=450)

NEJM1999

ZDV/3TC/EFV,

EFV/IDV,

ZDV/3TC/IDV

EFV regimen superior (?due to excess drop out with IDV)

Glaxo 3005 + 3014

ICAAC 1999 + 2000

ZDV/3TC/ABC,

ZDV/3TC/IDV

comparable VL response (?concern of baseline VL >100K)

Atlantic

(N=298)

Durban 2000

d4T/ddI/NVP,

d4T/ddI/IDV,

d4T/ddI/3TC

comparable VL responses

Combination Rx: 3-Drug Regimens


Dhhs treatment guidelines recommended alternatives

Column A

abacavir

amprenavir

delavirdine

nelfinavir + saquinavir

nevirapine

ritonavir

saquinavir sgc

Column B

ddI + 3TC

AZT + ddC

DHHS Treatment Guidelines:Recommended Alternatives

DHHS Guidelines, 1/28/00


Dhhs treatment guidelines other
DHHS Treatment Guidelines:Other

NO RECOMMENDATION; INSUFFICIENT DATA

  • hydroxyurea in combination regimens

  • ritonavir + indinavir

  • ritonavir + nelfinavir

    NOT RECOMMENDED; SHOULD NOT BE OFFERED

  • all monotherapies

  • saquinavir HGC

  • other 2 NRTIs: d4T + AZT, ddC + 3TC, ddC + d4T, ddC + ddI

DHHS Guidelines, 1/28/00


When to change case
When to change?Case

  • 35 year old woman

    • Recently diagnosed

    • History of oral thrush and zoster

    • HIV RNA 20,000

    • CD4 120

    • Tolerating her current regimen (ZDV/3TC/EFV) reasonably well


When to change case1
When to change?Case

  • Which of the following would be the STRONGEST reason to change therapy?

  • HIV RNA 600 cps/ml by 6 months.

  • CD4 increase of only +10 by 6 months.

  • Recurrence of zoster by 6 months.

  • Persistent mild nausea at 6 months.


Treatment failure clinical cohort studies

Clinical

Cohort

N

Failure rate

(% above LD, time)

Amsterdam

271

40% , 48 wks

Cleveland

310

53%, 1 yr

Hopkins

273

63%, 1 yr

Swiss

1517 exp

1157 naïve

38%, 2 yrs

20%, 2 yrs

UCSF

337

50%, 48 wks

Treatment Failure: Clinical Cohort Studies


When to change therapy
When to Change Therapy?

  • <0.5-0.75 log reduction in HIV RNA by 4 weeks or <1.0 log reduction by 8 weeks

  • failure to suppress HIV RNA BLD by 4-6 months

  • repeated detection of HIV RNA after suppression BLD

  • any reproducible significant increase of HIV RNA

  • undetectable viremia in pts taking dual nucs

  • persistently declining CD4 cell counts

  • clinical deterioration

DHHS Guidelines, 1/28/00


Why does treatment fail patients
Why Does Treatment Fail Patients?

  • adherence

  • side effects – acute and longer-term

  • baseline resistance or cross-resistance

  • use of less potent antiretroviral regimens

  • sequential monotherapy

  • drug levels and drug interactions

  • tissue reservoir penetration

  • other, unknown reasons


What to change to case f u
What to change to?Case (f/u)

  • At 6 months, you substituted d4T for ZDV, with resolution of nausea.

  • At 9 months of therapy with d4T/3TC/EFV, patient has HIV RNA 12,000 cps/ml.


What to change to case f u1
What to change to?Case (f/u)

  • You recommend all of the following EXCEPT:

  • Review adherence and tolerability

  • Confirm HIV RNA level

  • Check CD4 count

  • Substitute 3TC with ddI

  • Order genotype


What to change to
What to Change To?

  • very few clinical data to support specific strategies

  • use resistance testing

  • change at least two new drugs, and preferably at least three drugs

  • may be prudent to delay change in anticipation of new drugs

  • clinical expertise required

DHHS Guidelines, 1/28/00


Prospective studies of resistance testing in salvage rx

Study

Intervention

Results

VIRADAPT

(N=108)

Lancet 1999

genotype vs. none;

6 month f/u

genotype group had superior VL response

GART

(N=153)

AIDS 2000

genotype (with expert opinion) vs. none; 12 wk f/u

genotype group had superior VL response

VIRA 3001

(N=118)

Durban 2000

phenotype vs. none; 16 wk f/u

phenotype group had superior VL response

Prospective Studies ofResistance Testing in Salvage Rx


Dhhs monitoring guidelines
DHHS Monitoring Guidelines

  • Use of drug resistance assays

    • Recommended

      • virologic failure on HAART

      • suboptimal HIV RNA suppression after starting rx

    • Consider

      • acute HIV infection

    • Not generally recommended

      • chronic HIV infection, prior to rx

      • after discontinuation of drugs

      • HIV RNA <1000 copies/ml

DHHS Guidelines, 1/28/00


Investigational drugs 2000
Investigational Drugs: 2000

  • nucleoside RTI: DAPD/DXG, FTC

  • NNRTI: emivirine, capravirine, calanolide A, DPC 083 and 983

  • nucleotide RTI: tenofovir

  • protease inhibitors: tipranavir, BMS 232,632, Ag 1776, PD 178390, DPC 681 and 689

  • entry inhibitors:

    • fusion inhibitors: T-20, T-1249

    • chemokine receptor inhibitors: AMD-3100, TAK-799, Schering-C

    • CD4 attachment inhibitors: PRO 542

  • TAT inhibitors: CG 137053

  • integrase inhibitors:


Current approach to salvage rx
Current Approach to Salvage Rx

  • Review antiretroviral hx; assess adherence and tolerability

  • Distinguish first, second, multiple failures

  • Perform resistance testing while on drugs

  • Identify susceptible drugs/drug classes

  • Consider PK enhancement (RTV, DLV, HU)

  • Consider novel strategies (mega-HAART; STI)

  • Consider newer agents through expanded access or clinical trials

  • Design a regimen with >3 active drugs (if possible)


Sti s case
STI’s: CASE

  • 43 yo man, HIV+

    • Originally evaluated in 6/96 with CD4 52, HIV RNA 325K

    • Started d4T/3TC/IDV

    • HIV RNA <400 ever since (and in 8/00, <50)

    • Last CD4: 304 (5/00), 362 (8/00)

    • Calls Friday late afternoon from London to say that he’s flying to Katmandu tomorrow for a two week trek in the Himalayas and has lost his IDV


Question 1
QUESTION #1

  • What do you advise?

    1. cancel the trip and obtain meds in London ASAP

    2. take d4T and 3TC on the trip, resume 3 drugs on return

    3. take d4T only on the trip, resume 3 drugs on return

    4. take nothing on the trip, resume 3 drugs on return

    5. discontinue meds, check labs on return


Common reasons for stopping antiretrovirals
Common Reasons for Stopping Antiretrovirals

  • access

  • intercurrent illness

  • toxicities

  • surgery

  • first trimester of pregnancy

  • futility (virologic) in late-stage disease

  • non-adherence


Comet study
Comet Study

  • Ten antiretroviral naïve patients (baseline VL 63K, CD4 414)

  • Rx with ZDV/3TC/IDV X 28 days

  • Interrupted antiretrovirals X 28 days, VL rebound observed, then restarted meds

  • Viral load decline rate the same, no resistance-conferring mutations observed

  • With 4-12 months follow-up, VL <200 maintained


Treatment interruption 1
Treatment Interruption (1)

  • 837 subjects took 2 nucs + EFV or IDV on Dupont 006

  • 170 had d/c >2d for adverse event, then restarted later

  • for 82 with VL <400, ~70% reached <50

  • for 88 with VL >400, ~40% reached <50


Treatment interruption 2
Treatment Interruption (2)

  • 78 of 1246 clinic patients UAB had treatment interruption >30d, then resumed for >30d

  • prior to interruption, VL 9K, CD4 230

  • after interruption, VL 400, CD4 230 (best response)

  • 59% reached 90% of prior CD4

  • 77% reached within 0.3 logs of prior VL


Case 1 follow up
CASE #1 FOLLOW-UP

  • Patient decides to proceed with the trip, and not to take any antiretrovirals.

  • 3 weeks later, he present with no complaints and asks about “doing an STI.”


Question 11
QUESTION #1

  • Have you had a patient ask to “do an STI”?

  • Yes

  • No


Question 2
QUESTION #2

  • Have you used an STI as part of the management of an HIV-infected patient (to effect virologic/immunologic status)?

    1. Yes

    2. No


Clinical rationale for sti
Clinical Rationale for STI

  • Issues with antiretroviral regimens

    • adherence

    • toxicity

    • quality of life

    • cost

  • viral eradication not possible


Sti the hypothesis
STI: The Hypothesis

In patients with virologic suppression on therapy:

  • Discontinuing therapy with viral rebound will re-stimulate HIV specific immune responses.

  • These immune responses will be able to control viremia without antiretroviral therapy.


Clinical settings for sti
Clinical Settings for STI

  • Acute infection with virologic suppression on antiretrovirals

    • Preserve/stimulate HIV-specific cellular responses

  • Chronic infection with virologic suppression on antiretrovirals

    • stimulate HIV-specific cellular responses and/or provide a break from therapy

  • Virologic failure

    • promote reversion to wild type virus; improve activity of subsequent regimen


Sti in acute hiv infection
STI in Acute HIV Infection

  • 8 patients with acute/recent HIV infection treated with antiretrovirals (VL <50 X >8 months)

  • All underwent STI and all experienced viral rebound; 3 pts had VL <5000 and remained off rx

  • Other 5 underwent second STI after resuppression and 2 maintained VL <500 X 5-6 months off meds

  • HIV-specific CD4 responses maintained/augmented and CTL responses augmented/broadened

Rosenberg, Nature 2000


Sti in chronic hiv suppression
STI in Chronic HIV Suppression

  • SSITT study: The Swiss-Spanish Intermittent Trial

  • 122 subjects on HAART, VL <50 and CD4 >300

  • STI cycles: d/c X 2 wks, rx X 8 wks (4 cycles)

  • 9 of 54 (17%) had VL <5K, 3 of 54 (6%) VL <50

  • No clear changes in VL rebound levels, p24 specific CD4 IR increased, one subject developed 3TC and PI resistance, 2 had acute retroviral syndrome

Hirschel, Durban 2000


Sti risks
STI: Risks

  • repopulate reservoirs

  • virologic rebound and resistance

  • CD4 decline

  • clinical

    • acute antiretroviral syndrome

    • AIDS-defining illness


Antiretroviral therapy conclusions 1
Antiretroviral Therapy: Conclusions (1)

  • The optimal time to start rx is not clear.

  • The optimal initial rx regimen is not clear.

  • There are many effective combination regimens available.

  • First line rx fails in 10-60% of patients.


Antiretroviral therapy conclusions 2
Antiretroviral Therapy: Conclusions (2)

  • Better “salvage therapy” regimens are needed.

  • Resistance testing demonstrates benefits in selecting antiretroviral therapy.

  • There are a number of new drugs in development, both in existing classes and drugs with new mechanisms of action.


Antiretroviral therapy conclusions 3
Antiretroviral Therapy: Conclusions (3)

  • It is too early to recommend the routine use of STI in any clinical setting.

  • Prospective, randomized, controlled studies are needed to establish the risks and benefits of STI’s.

  • Further research is needed.


ad